EP
ARCT icon

Eversept Partners’s Arcturus Therapeutics ARCT Stock Holding History

Eversept Partners’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-48,364
Closed -$629K – 88
2025
Q2 		$629K Buy
+48,364
New +$572K 0.06% 65

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Eversept Partners's ARCT Position: Q3 2025 in Review

Eversept Partners sold out of Arcturus Therapeutics (ARCT) in Q3 2025, closing a stake of 48,364 shares — an estimated $629K sold.

Eversept Partners first reported a position in ARCT in Q2 2025 and held it in 1 quarter. The position peaked at $629K in Q2 2025. 136 funds tracked by Wall St. Rank hold ARCT as of Q3 2025.

  • Eversept Partners reported no remaining Arcturus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Eversept Partners sold 48,364 Arcturus Therapeutics shares in Q3 2025, an estimated $629K.
  • Eversept Partners first reported a position in Arcturus Therapeutics in Q2 2025 and held it in 1 quarter.
  • Eversept Partners's Arcturus Therapeutics position peaked at $629K in Q2 2025.
  • 136 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2025.

Based on Eversept Partners's 13F filing for Q3 2025, filed 14 Nov 2025.